MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • Noticias
  • Store
  • Corredores
  • Descargar
  • Calendario económico
  • Señales Comerciales
  • WebTerminal
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Italiano Italiano
  • Türkçe Türkçe
Apellis Pharmaceuticals, Inc. Common Stock

APLS

#1497
Apellis Pharmaceuticals, Inc. Common Stock
20.96
-4.42%
Sector:
Básica:
Profit Currency:
Rango diario
20.96
20.96
Rango anual
16.10
30.48
Cambio diario
-4.42%
Monthly Change
-6.05%
6 month change
-26.71%
Cambio anual
-19.38%
Cierres anteriores
21.93
Open
20.96
Bid
Ask
Low
20.96
High
20.96
Volumen
127
  1. Markets
  2. Acciones
  3. Atención Sanitaria
  4. APLS
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
Value 202020212022202320242025 TTM

Noticias

Zacks Zacks
APLS CSTL HRMY IMCR
2026.02.25
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
Investing Investing
APLS
2026.02.25
H.C. Wainwright relève l’objectif de cours d’Apellis sur les perspectives de Syfovre
Investing Investing
APLS
2026.02.25
H.C. Wainwright raises Apellis stock price target on Syfovre outlook
Seeking Alpha Seeking Alpha
APLS
2026.02.24
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
Investing Investing
APLS
2026.02.24
Le BPA de Apellis Pharma a dépassé les attentes de 0,85$, le CA a surpassé les prévisions
Investing Investing
APLS
2026.02.24
Apellis Pharma earnings beat by $0.85, revenue topped estimates
Zacks Zacks
APLS FENC
2026.02.24
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
Investing Investing
APLS
2026.02.24
Résultats T4 2025 d’Apellis : croissance des deux produits
Investing Investing
APLS
2026.02.24
Apellis Q4 2025 slides: dual product growth, path to profitability
Seeking Alpha Seeking Alpha
APLS
2026.02.24
Apellis Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:APLS) 2026-02-24
Investing Investing
APLS
2026.02.23
Résultats d’Apellis : le nouveau médicament rénal peut-il relancer la croissance ?
Investing Investing
APLS
2026.02.23
Apellis earnings on deck: Can new kidney drug revive growth momentum?

Markets

  • Acciones
  • Divisas
  • Criptomonedas
  • Metales
  • Mercancías

Charts & Ideas

  • Ideas comerciales
  • Ideas ilustrativas
  • Gráfico

MQL5 Community

  • Market
  • Señales
  • Foro
  • Artículos
  • CodeBase

Noticias

  • Acciones
  • Divisas
  • Criptomonedas
  • Metales
  • Mercancías

Corredores

  • Todos los brókeres
  • Fórex
  • Acciones
  • Metales
MetaTrader 5
MQL5 Channels
Economic Calendar
Disclaimer and Risk Disclosure Terms of Use Información y contacto Legal
Copyright 2000-2026, MetaQuotes Ltd